Animas acquired
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/LifeScan completes its acquisition of the West Chester, Penn.-based insulin delivery system manufacturer Feb. 17. Animas, which will operate as an independent entity, expects to bring its GlucoWatch G3 continuous glucose monitoring system to market in 2006 (1"The Gray Sheet" Dec. 19, 2005, p. 3)...
You may also be interested in...
Johnson & Johnson Snags Animas To Advance Artificial Pancreas Design
Johnson & Johnson/LifeScan will acquire long-sought access to the continuous glucose monitoring system (CGMS) market with its $518 mil. purchase of Animas, the firm announced Dec. 16
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.